Appendix 2

Reviewer Relationships With Industry and Other Entities (Relevant)—2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

ReviewerRepresentationConsultantSpeaker's BureauOwnership/ Partnership/ PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
Elliott M. AntmanOfficial Reviewer—ACCF Board of TrusteesNoneNoneNone
  • Accumetrics

  • AstraZeneca

  • Beckman Coulter

  • Bristol-Myers Squibb Pharmaceutical Research Institute

  • Daiichi-Sankyo

  • Eli Lilly

  • GlaxoSmithKline

  • Merck

  • Millennium Pharmaceuticals

  • Novartis Pharmaceuticals

  • Ortho-Clinical Diagnostics

  • Sanofi-Synthelabo Recherche

  • Schering-Plough Research Institute

NoneNone
Gary J. BaladyOfficial Reviewer—AHANoneNoneNoneNoneNoneNone
Christopher P. CannonOfficial Reviewer—AHA
  • Novartis

NoneNone
  • Accumetrics

  • AstraZeneca

  • Bristol-Myers Squibb

  • GlaxoSmithKline

  • Merck

  • GlaxoSmithKline

  • Merck (DSMB)

None
Judith S. HochmanOfficial Reviewer—ACCF/AHA Task Force on Practice Guidelines
  • BMS/Sanofi

  • Eli Lilly

  • GlaxoSmithKline

NoneNoneNone
  • Johnson & Johnson Pharmaceutical Research & Development (DSMB)

  • Merck/Schering Plough (DSMB)

None
Austin H. KutscherOfficial Reviewer—ACCF Board of GovernorsNoneNoneNoneNoneNoneNone
Charles J. DavidsonOrganizational Reviewer—SCAI
  • Abbott

  • Abbott Vascular

NoneNone
  • Edwards Lifesciences

NoneNone
Deborah B. DiercksOrganizational Reviewer—ACEP
  • Abbott Cardiovascular

  • Daiichi-Sankyo

NoneNone
  • Beckman Coulter

  • Nanosphere

NoneNone
Jonathan M. TobisOrganizational Reviewer—SCAINone
  • AGA Medical

  • Boston Scientific

None
  • AGA Medical

NoneNone
Jeffrey L. AndersonContent Reviewer— ACCF/AHA Task Force on Practice GuidelinesNoneNoneNone
  • Toshiba

  • AstraZeneca (DSMB)

  • Defendant, Postoperative Ablation Case, 2010

James C. BlankenshipContent ReviewerNoneNoneNone
  • AstraZeneca

  • Boston Scientific

  • Novartis

  • Schering-Plough

NoneNone
Jeffrey J. CavendishContent Reviewer—ACCF Prevention of Cardiovascular Disease CommitteeNoneNoneNoneNoneNoneNone
Harold L. DauermanContent ReviewerNoneNoneNoneNoneNoneNone
John S. Douglas, Jr.Content ReviewerNoneNoneNone
  • Abbott

  • Medtronic

  • The Medicines Company

NoneNone
Stephen G. EllisContent Reviewer
  • Abbott Vascular

  • Boston Scientific

NoneNoneNoneNoneNone
Joseph FrediContent Reviewer—ACCF Surgeons' Scientific Council
  • AGA Medical

NoneNoneNoneNoneNone
Anthony GershlickContent Reviewer
  • Abbott

  • AstraZeneca

  • Boehringer Ingelheim

  • Boston Scientific

  • Cordis

  • Eli Lilly

  • Medtronic

NoneNone
  • Boehringer Ingelheim

NoneNone
Howard C. HerrmannContent Reviewer
  • AstraZeneca

  • Merck Sharpe and Dohme

NoneNone
  • Accumetrics

  • Boston Scientific

  • Edwards Lifesciences

  • eValve

  • Medtronic

  • St. Jude Medical

  • The Medicines Company

NoneNone
James Bernard HermillerContent Reviewer—ACCF Interventional Scientific Council
  • Abbott

  • Boston Scientific

  • St. Jude Medical

  • Eli Lilly

NoneNoneNoneNone
Fred M. KosumotoContent ReviewerNoneNoneNoneNoneNoneNone
Glenn LevineContent ReviewerNoneNoneNoneNoneNoneNone
Roxana MehranContent Reviewer
  • Abbott Vascular

  • AstraZeneca

  • Ortho-McNeill

NoneNone
  • BMS/Sanofi-aventis

  • The Medicines Company

NoneNone
M. Eugene ShermanContent Reviewer—ACCF Board of GovernorsNoneEli LillyNoneNoneNoneNone
Daniel I. SimonContent Reviewer
  • Cordis/Johnson & Johnson

  • Daiichi-Sankyo

  • Eli Lilly

  • Medtronic

  • Sanofi-aventis

  • The Medicines Company

NoneNoneNoneNone
  • Defendant, DES Intellectual Property Case, 2010

Richard W. SmallingContent Reviewer—ACCF Interventional Scientific Council
  • AGA Medical

NoneNone
  • AGA Medical

  • Cordis

  • eValve

  • AGA Medical

  • Cordis

  • eValve

None
William G. StevensonContent Reviewer— ACCF/AHA Task Force on Practice GuidelinesNoneNoneNoneNoneNoneNone
William A. Tansey IIIContent ReviewerNoneNoneNoneNoneNoneNone
David D. WatersContent Reviewer
  • Bristol-Myers Squibb

  • Pfizer

NoneNoneNone
  • Merck/Schering-Plough

  • Sanofi-aventis (DSMB)

None
Christopher J. WhiteContent ReviewerNoneNoneNone
  • Boston Scientific

  • St. Jude Medical

NoneNone
Clyde W. YancyContent Reviewer— ACCF/AHA Task Force on Practice GuidelinesNoneNoneNoneNoneNoneNone
Yerem YeghiazariansContent ReviewerNoneNoneNoneNoneNoneNone

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

According to the ACCF/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person's household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

ACCF indicates American College of Cardiology Foundation; ACEP, American College of Emergency Physicians; AHA, American Heart Association; DES, drug-eluting stent; DSMB, data safety monitoring board; and SCAI, Society for Cardiovascular Angiography and Interventions.

  • Significant relationship.

  • No financial benefit.